Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL9128017 | 0.85 | IDO1 (0.45) | IDO1TDO2USP2TDP1ALDH1A1 | |
| SCHEMBL9130369 | 0.80 | ALDH1A1 (0.40) | IDO1TDO2USP2ALDH1A1POLB | |
| SCHEMBL19955179 | 0.78 | TDP1 (0.66) | USP2TDP1ALDH1A1MAPTMAPK10 | |
| SCHEMBL31738422 | 0.78 | TDP1 (0.66) | USP2TDP1ALDH1A1MAPTMAPK10 | |
| SCHEMBL395878 | 0.78 | TDP1 (0.66) | USP2TDP1ALDH1A1MAPTMAPK10 | |
| Threonine SCHEMBL9838841 | 0.77 | USP2 (0.48) | USP2TDP1ALDH1A1MAPTMAPK10 | |
| Threonine SCHEMBL9838836 | 0.77 | USP2 (0.48) | USP2TDP1ALDH1A1MAPTMAPK10 | |
| Nitrous Acid SCHEMBL7062049 | 0.74 | TDP1 (0.56) | USP2TDP1ALDH1A1MAPTMAPK10 | |
| SCHEMBL9402119 | 0.72 | USP2 (0.42) | USP2TDP1ALDH1A1MAPTMAPK10 | |
| Benzil SCHEMBL6523597 | 0.72 | CES2 (0.52) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144613-B2 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20170362626-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20160244798-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2016-08-25 | — | — | US | disclosed |
| EP-2305804-B1 | MonoPEGylated human growth hormone | BOLDER BIOTECHNOLOGY INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8957023-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8932828-B2 | Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins | BOLDER BIOTECHNOLOGY, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130217629-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8288126-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120064573-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-03-15 | — | — | US | disclosed |
| EP-1144613-B1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7306931-B2 | Lysis, denaturing, reducing Growth hormones | BOLDER BIOTECHNOLOGY, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1284987-B1 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20050187160-A1 | Monopegylated growth hormone proteins | BOLDER BIOTECHNOLOGY INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-6753165-B1 | FOR RESIDUES THAT DO NOT FORM DISULFIDE BOND | BOLDER BIOTECHNOLOGY, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20040018586-A1 | Lysis, denaturing, reducing Growth hormones | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1284987-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1144613-A4 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2002-10-29 | — | — | EP | disclosed |
| WO-2001087925-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-1144613-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042175-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC. (US) | 2000-07-20 | — | — | WO | disclosed |